A retrospective analysis of 414 ALK-positive NSCLC patients enrolled in PROFILE 1001 and PROFILE 1005 showed that continuation of crizotinib (>3 weeks) after progression conferred extended progression time and longer OS (180). Here, ALK is linked to non-small cell lung carcinoma.